Core Insights - Shuttle Pharmaceuticals is advancing its Phase 2 clinical trial of Ropidoxuridine for glioblastoma treatment, having successfully dosed the first three patients [1][2] - The company has finalized agreements with six clinical trial sites, including major cancer centers, to conduct the trial [1][2] - Shuttle Pharma has improved its financial position by paying off a $4.3 million convertible note and completing a $4.5 million public offering [1][2] Company Developments - The Phase 2 clinical trial will enroll 40 patients with IDH wild-type, methylation negative glioblastoma, aiming to determine the optimal dose of Ropidoxuridine [3] - The trial is expected to take 18 to 24 months to complete, with the primary endpoint being survival compared to historical controls [3] - The company aims to leverage radiation sensitizers to enhance cancer treatment outcomes and improve patient quality of life [6] Market Opportunity - Approximately 800,000 patients in the US receive radiation therapy for cancer annually, with 400,000 treated for curative purposes [4] - The market for radiation sensitizers is projected to grow by over 22% in the next five years, indicating significant potential for Shuttle Pharma's products [4]

GAITHERSBURG, Md., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) ("Shuttle Pharma"), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), announced today it has finalized agreements with all six of the planned site enrollment locations to administer the Phase 2 clinical trial of Ropidoxuridine for the treatment of patients with glioblastoma following the entry into a ...

GAITHERSBURG, Md., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) ("Shuttle Pharma"), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), announced today it has entered into agreements with two additional site locations to administer the Phase 2 clinical trial of Ropidoxuridine for the treatment of patients with glioblastoma. Four of the planned six trial sites are ...

GAITHERSBURG, Md., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) ("Shuttle Pharma"), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today provided a corporate update in connection with the filing of its Quarterly Report on Form 10-Q for the second quarter ended June 30, 2024. Shuttle Pharma's recent highlights include the following: Enrollment of patients in t ...

GAITHERSBURG, Md., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) ("Shuttle Pharma"), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), announced today it has entered into agreements with two of the six site locations to administer the Phase 2 clinical trial of Ropidoxuridine for the treatment of patients with glioblastoma. Site initiation visits have been complete ...

Core Insights - Shuttle Pharmaceuticals Holdings, Inc. has published a manuscript demonstrating the effectiveness of its HDAC inhibitor SP-1-303 in inhibiting the growth of estrogen receptor positive breast cancer cells [1][6] - The CEO of Shuttle Pharmaceuticals emphasized the potential of SP-1-303 as a promising therapeutic approach for treating estrogen receptor positive breast cancers through combined targeting of Class I HDACs and ATM [2] Company Overview - Founded in 2012 by faculty members of Georgetown University Medical Center, Shuttle Pharmaceuticals focuses on improving outcomes for cancer patients undergoing radiation therapy [5] - The company's mission is to enhance the effectiveness of radiation therapy while minimizing side effects, aiming to increase cancer cure rates and improve patient quality of life [5] Research and Development - The published manuscript titled "Dual-targeting class I HDAC inhibitor and ATM activator, SP-1-303, preferentially inhibits estrogen receptor positive breast cancer cell growth" was authored by Dr. Mira Jung and Dr. Scott Grindrod [6] - SP-1-303 is a selective Class I HDAC inhibitor that shows direct cellular toxicity in estrogen receptor positive breast cancer and enhances PD-L1 expression, suggesting potential for combination with immune checkpoint blockers [7]

SP-1-303, initially discovered and synthesized in Shuttle Pharma's laboratories by Dr. Grindrod, is one of the Company's pre-clinical selective Class I HDAC inhibitors. Histone deacetylase inhibitors sensitize cancers to the effects of radiation, protect normal tissues from radiation injury and activate the immune system. SP-1-303 is a selective Class I HDAC inhibitor that inhibits HDAC1, 3 and 6 and has direct cellular toxicity in ER + BC. Furthermore, SP-1-303 increases the PD-L1 expression level in a tim ...

Mr. Lorber is a CPA with more than 40 years of professional finance experience, including 15 years with Legg Mason, Inc. ("Legg Mason"), one of the world's larger public global asset management firms where he served as a Managing Director and Chief Accounting Officer until its sale in 2020. More recently, Mr. Lorber has served in leadership roles with several privately held businesses, overseeing finance, IT and HR functions. Prior to Legg Mason, Mr. Lorber served as Internal Audit Director of Freddie Mac a ...

GAITHERSBURG, Md., May 22, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced that Dr. Anatoly Dritschilo, Chief Executive Officer, will participate in a webcasted presentation and host one-on-one meetings with investors at the Lytham Partners Spring 2024 Investor Conference, taking place virtually on Thursday ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2024 (Exact name of registrant as specified in its charter) Delaware 001-41488 82-5089826 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 401 Professional Drive, Suite 260 Gaithersburg, MD 20879 (Address of principal executive of ...